Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

1,001 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Doxorubicin plus dacarbazine, doxorubicin plus ifosfamide, or doxorubicin alone as a first-line treatment for advanced leiomyosarcoma: A propensity score matching analysis from the European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group.
D'Ambrosio L, Touati N, Blay JY, Grignani G, Flippot R, Czarnecka AM, Piperno-Neumann S, Martin-Broto J, Sanfilippo R, Katz D, Duffaud F, Vincenzi B, Stark DP, Mazzeo F, Tuchscherer A, Chevreau C, Sherriff J, Estival A, Litière S, Sents W, Ray-Coquard I, Tolomeo F, Le Cesne A, Rutkowski P, Stacchiotti S, Kasper B, Gelderblom H, Gronchi A; European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group. D'Ambrosio L, et al. Among authors: blay jy. Cancer. 2020 Jun 1;126(11):2637-2647. doi: 10.1002/cncr.32795. Epub 2020 Mar 4. Cancer. 2020. PMID: 32129883 Free article.
Intravenous interleukin-2 in patients over 65 with metastatic renal carcinoma.
Négrier S, Mercatello A, Bret M, Thiesse P, Blay JY, Coronel B, Merrouche Y, Oskam R, Franks CR, Clavel M, et al. Négrier S, et al. Among authors: blay jy. Br J Cancer. 1992 May;65(5):723-6. doi: 10.1038/bjc.1992.152. Br J Cancer. 1992. PMID: 1586600 Free PMC article. Clinical Trial.
Effect of high-dose ifosfamide in advanced soft tissue sarcomas. A multicentre phase II study of the EORTC Soft Tissue and Bone Sarcoma Group.
Nielsen OS, Judson I, van Hoesel Q, le Cesne A, Keizer HJ, Blay JY, van Oosterom A, Radford JA, Svancárová L, Krzemienlecki K, Hermans C, van Glabbeke M, Oosterhuis JW, Verweij J. Nielsen OS, et al. Among authors: blay jy. Eur J Cancer. 2000 Jan;36(1):61-7. doi: 10.1016/s0959-8049(99)00240-3. Eur J Cancer. 2000. PMID: 10741296 Clinical Trial.
Randomized phase III study comparing conventional-dose doxorubicin plus ifosfamide versus high-dose doxorubicin plus ifosfamide plus recombinant human granulocyte-macrophage colony-stimulating factor in advanced soft tissue sarcomas: A trial of the European Organization for Research and Treatment of Cancer/Soft Tissue and Bone Sarcoma Group.
Le Cesne A, Judson I, Crowther D, Rodenhuis S, Keizer HJ, Van Hoesel Q, Blay JY, Frisch J, Van Glabbeke M, Hermans C, Van Oosterom A, Tursz T, Verweij J. Le Cesne A, et al. Among authors: blay jy. J Clin Oncol. 2000 Jul;18(14):2676-84. doi: 10.1200/JCO.2000.18.14.2676. J Clin Oncol. 2000. PMID: 10894866 Clinical Trial.
1,001 results